Nitrosamine Impurities; What’s the Impact on IMPs
October 13, 2020
N-nitrosamines are a regulatory and industry hot topic and whilst the focus has been on marketed products rather than development portfolios, there is an impact on investigational medicinal product development and manufacture. This webinar, led by Paul Cummings, will discuss nitrosamine impurities including key considerations when developing an IMP, the risks of delaying a formal risk assessment and more.
How NSF Can Help You
Get in touch to find out how we can help you and your business thrive.
What’s New with NSF
iNADO Partners with NSF to Support Members and Athletes
May 27, 2026iNADO is pleased to welcome NSF’s expertise and experience in support of its members and the athletes they serve
NSF Ends UK’s Three-Year Testing Gap with REG 31 Testing Designation
May 20, 2026NSF’s Oakdale laboratory becomes the UK’s sole facility offering comprehensive BS 6920 and REG 31 testing, closing a critical drinking water safety gap.
NSF Annual Review and Impact Report 2025 Now Live
April 20, 2026NSF has published its Annual Review and Impact Report 2025, detailing the organization’s progress over the past year and outlining strategic priorities for 2026.
Visit NSF at Making Pharma 2026
April 10, 2026Connect with our experts to discover how we help leading pharmaceutical and biotechnology companies achieve regulatory compliance and operational excellence.